T cell-based HIV gene therapy safe over long term

T cell-Based HIV gene therapy safe over long term

(HealthDay) -- T cell-based gene therapy for HIV seems safe, with no evidence of vector-induced cell immortalization more than a decade after treatment, according to a study published in the May 2 issue of Science Translational Medicine.

John Scholler, from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues performed a follow-up of HIV-infected patients who had received consisting of engineered with linked to the CD3ζ signaling chain as part of three clinical trials at least eleven years earlier.

The researchers found that the engineered T cells were still detectable in 98 percent of samples, with no evidence of vector-induced immortalization. There was no evidence of persistent clonal expansion or enrichment for integration sites near genes implicated in transformation or growth control. The modified cells were stably engrafted, with a half-life of at least 16 years, and remained functional.

"Our results emphasize the safety of T cells modified by retroviral gene transfer in clinical application, as measured in >500 patient-years of follow-up," Scholler and colleagues conclude. "Thus, previous safety issues with integrating viral vectors are hematopoietic stem cell or transgene intrinsic, and not a general feature of retroviral vectors."

One author is employed by Celgene; another author disclosed working as an advisor and clinical investigator for biopharmaceutical companies.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

The promise of stem cell-based gene therapy

Jun 27, 2011

Sophisticated genetic tools and techniques for achieving targeted gene delivery and high gene expression levels in bone marrow will drive the successful application of gene therapy to treat a broad range of ...

Recommended for you

HIV testing yields diagnoses in Kenya but few seek care

Jan 29, 2015

Between December 2009 and February 2011, health workers with the AMPATH Consortium sought to test and counsel every adult resident in the Bunyala subcounty of Kenya for HIV. A study in the journal Lancet HIV reports that the campaign yielded more than 1,300 new positive diagnoses, but few of those new ...

The adaptability of pathogens

Jan 28, 2015

Drug-resistant HIV viruses can spread rapidly. This is the conclusion of a study conducted as part of the SWISS HIV Cohort Study, which is supported by the SNSF. Only the continuous introduction of new drugs can stop the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.